PATENT CLAIM ANALYSIS

Application Number: 16101298
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-01
Patent Classification: ["424", "400000"]

Abstract:
The disclosure provides methods for treating psychiatric diseases, such as schizophrenia, in patients with certain gene polymorphisms using antipsychotic drugs, such as risperidone and paliperidone.

Claim (Index 5):
A method to produce therapeutic concentrations of risperidone and 9-hydroxyrisperidone after a first injection of a risperidone composition without use of an oral risperidone medication in a schizophrenic patient in need thereof, the method comprising subcutaneously injecting the patient with the risperidone composition without administration of the oral risperidone medication; wherein the risperidone composition comprises about 90 mg or about 120 mg of risperidone base at a concentration of about 15 wt %; about 38 wt % of a poly(lactide-co-glycolide)copolymer; and about 47 wt % N-methyl-2-pyrrolidone.

Metadata:
- Claim Count in Document: 71.0
- Percentile: 96.0
- Lexical Diversity: 1.16
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15122101', '15858525', '12602058', '16016250', '14490034']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7676697249229784
- 35 USC 102 Novelty (BERT): 0.6085248238636446
- Combined Prediction Score: 0.751755234817045
- Mean Citation Score: 317.977906
- Max Citation Score: 348.78464
- Similarity Product: 242.32318423706056

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test